Refine by
Clinical Trial Data Articles & Analysis: Older
469 news found
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it ...
ByTempus
Introduction Intraoperative irrigation is a commonly used method aimed at reducing microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field prior to site closure.1 With the absence of universally established standard of care and robust clinical data, the selection of appropriate irrigation solution remains a topic of debate. Isotonic saline has ...
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
Caresyntax, the leading vendor-neutral surgical data and intelligence platform converging AI-powered software, devices, and clinical services, today announced the launch of Caresyntax Clinical Data as a Service (CDaaS) for Medtech industry partners. The launch of Caresyntax CDaaS follows the recently announced addition of CQInsights (CQI) and appointment of Dr. Bruce Ramshaw as Chief Medical ...
Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and artificial intelligence solutions throughout the UAE, US, and Europe. With this strategic engagement, the companies will combine their healthcare datasets and delivery resources to offer bundled software and services solutions to healthcare ...
Caresyntax, the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer by converging AI-powered software, devices, and clinical services, today announced a partnership with ARC (Accelerate, Redesign, Collaborate) Sheba’s Global Innovation platform to establish and replicate the ARC Surgical Innovation Model using the Caresyntax ...
With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. ...
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
The following new abstracts for aflibercept 8 mg will be presented at ARVO 2023: The pooled safety analysis compares the safety of aflibercept 8 mg with aflibercept 2 mg across the clinical trial program which includes data from the phase II trial CANDELA in nAMD and the pivotal phase II/III trial PHOTON in DME ...
ByBayer AG
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...
ByBayer AG
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
A sure sign of a quality organization is the ability to measure its progress and success. “In business, words are words; explanations are explanations, promises are promises, but only performance is reality,” according to Harold S. Geneen, CEO of International Telephone and Telegraph Corp. With the continuous upward trend in productivity of the pharmaceutical ...
Even in pre-pandemic times, clinical trials have always been an ongoing process. Clinical trial managers work on cutting-edge studies and contribute to developing drugs and devices. ...
Critical workflows in Oncology Informatics, such as clinical trial matching and cancer registry reporting and data abstraction, are ripe for disruption through the powerful and clinically optimized AI (artificial intelligence) and NLP (Natural Language Processing) technology that Inspirata has been developing over two decades. ...
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...